CA2506340A1 - Novel lapachone compounds and methods of use thereof - Google Patents

Novel lapachone compounds and methods of use thereof Download PDF

Info

Publication number
CA2506340A1
CA2506340A1 CA002506340A CA2506340A CA2506340A1 CA 2506340 A1 CA2506340 A1 CA 2506340A1 CA 002506340 A CA002506340 A CA 002506340A CA 2506340 A CA2506340 A CA 2506340A CA 2506340 A1 CA2506340 A1 CA 2506340A1
Authority
CA
Canada
Prior art keywords
substituted
unsubstituted
compound
formula
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002506340A
Other languages
English (en)
French (fr)
Inventor
Zhiwei Jiang
Dasharatha Reddy
Samuel K. Ackerman
June Salvesen
Xiangao Sun
Chiang Li
Youzhi Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arqule Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2003/022631 external-priority patent/WO2004007531A2/en
Application filed by Individual filed Critical Individual
Publication of CA2506340A1 publication Critical patent/CA2506340A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/08—Naphthothiopyrans; Hydrogenated naphthothiopyrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92—Naphthofurans; Hydrogenated naphthofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/92—Naphthopyrans; Hydrogenated naphthopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/06—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/74—Naphthothiophenes

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CA002506340A 2002-11-18 2003-11-18 Novel lapachone compounds and methods of use thereof Abandoned CA2506340A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US42728302P 2002-11-18 2002-11-18
US60/427,283 2002-11-18
US10/622,854 2003-07-17
PCT/US2003/022631 WO2004007531A2 (en) 2002-07-17 2003-07-17 Activated checkpoint therapy and methods of use thereof
US10/622,854 US20040209942A1 (en) 2002-07-17 2003-07-17 Activated checkpoint therapy and methods of use thereof
USPCT/US03/22631 2003-07-17
PCT/US2003/037219 WO2004045557A2 (en) 2002-11-18 2003-11-18 Novel lapachone compounds and methods of use thereof

Publications (1)

Publication Number Publication Date
CA2506340A1 true CA2506340A1 (en) 2004-06-03

Family

ID=34375156

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002506340A Abandoned CA2506340A1 (en) 2002-11-18 2003-11-18 Novel lapachone compounds and methods of use thereof

Country Status (12)

Country Link
US (1) US20040266857A1 (enExample)
EP (1) EP1567515A4 (enExample)
JP (1) JP2006508147A (enExample)
CN (1) CN1729183A (enExample)
AR (1) AR056613A1 (enExample)
AU (1) AU2003295738A1 (enExample)
BR (1) BR0316296A (enExample)
CA (1) CA2506340A1 (enExample)
EA (1) EA200500849A1 (enExample)
MX (1) MXPA05005314A (enExample)
TW (1) TW200510367A (enExample)
WO (1) WO2004045557A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004050033A2 (en) 2002-12-02 2004-06-17 Arqule, Inc. Method of treating cancers
WO2005053682A2 (en) 2003-11-26 2005-06-16 Arqule, Inc. Use of beta-lapachone for protecting against radiation injury
WO2005082353A2 (en) * 2004-02-20 2005-09-09 Arqule, Inc. Use of beta-lapachone for treating or preventing cancer
WO2005082359A2 (en) * 2004-02-20 2005-09-09 Arqule, Inc. Use of beta-lapachone for the treatment of pancreatic cancer
CA2556794A1 (en) * 2004-02-20 2005-09-09 Arqule, Inc. Use of beta-lapachone as a broad spectrum anti-cancer agent
CA2556789A1 (en) * 2004-02-20 2005-09-09 Arqule, Inc. Use of beta-lapachone for treating hematologic tumors
US20050187288A1 (en) * 2004-02-20 2005-08-25 Chiang Li Beta-lapachone and methods of treating cancer
EP2033640A2 (en) 2004-02-20 2009-03-11 Arqule, Inc. Beta-lapachone for the treatment of lung cancer
JP2007523189A (ja) 2004-02-20 2007-08-16 アークル・インコーポレーテツド 結腸癌の治療のためのβ−ラパコンの使用
CA2583700A1 (en) 2004-08-11 2006-02-23 Arqule, Inc. Quinone prodrug compositions and methods of use
US8614228B2 (en) 2004-08-11 2013-12-24 Arqule, Inc. Quinone prodrug compositions and methods of use
EP1836320A2 (en) 2005-01-07 2007-09-26 Arqule, Inc. Compositions for modulation of parp and methods for screening for same
WO2006128120A2 (en) * 2005-05-26 2006-11-30 Arqule, Inc. Novel lapachone compounds and methods of use thereof
WO2007139569A1 (en) * 2006-05-26 2007-12-06 Arqule, Inc. Novel lapachone compounds and methods of use thereof
TW200824692A (en) 2006-08-21 2008-06-16 Arqule Inc Novel lapachone compounds and methods of use thereof
WO2008115804A1 (en) * 2007-03-16 2008-09-25 Lankenau Institute For Medical Research Novel ido inhibitors and methods of use thereof
WO2008134088A1 (en) 2007-04-30 2008-11-06 Arqule, Inc. Hydroxy sulfonate of quinone compounds and their uses
US8067459B2 (en) 2007-10-16 2011-11-29 Arqule, Inc. Lapachone compounds and methods of use thereof
KR101405823B1 (ko) * 2007-12-24 2014-06-12 주식회사 케이티앤지생명과학 녹내장의 치료 및 예방을 위한 약제 조성물
KR20090071829A (ko) * 2007-12-28 2009-07-02 주식회사 머젠스 신장질환의 치료 및 예방을 위한 약제 조성물
KR20090073381A (ko) * 2007-12-31 2009-07-03 주식회사 머젠스 심장질환의 치료 및 예방을 위한 약제 조성물
SG10201506942VA (en) * 2010-06-01 2015-10-29 Belle Aire Fragrances Inc Oral odor control method and product
WO2017106624A1 (en) 2015-12-18 2017-06-22 The Board Of Regents Of The University Of Texas System Napthoquinones, pro-drugs, and methods of use thereof
KR101735275B1 (ko) 2016-12-20 2017-05-16 아주대학교산학협력단 베타-라파촌을 포함하는 수면 장애 예방 또는 치료용 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2011455B (en) * 1977-12-21 1982-03-03 Ici Ltd Chemical process
US5346917A (en) * 1991-06-10 1994-09-13 Sterling Winthrop Inc. Thioxanthenone antitumor agents
US5763625A (en) * 1995-04-25 1998-06-09 Wisconsin Alumni Research Foundation Synthesis and use of β-lapachone analogs
US6245807B1 (en) * 1995-08-24 2001-06-12 Dana-Farber Cancer Institute Treatment of human prostate disease
US5883270A (en) * 1996-02-20 1999-03-16 Wisconsin Alumni Research Foundation 4-substituted-1, 2-naphthoquinones and their use in the inhibition of neoplastic cell growth
US5824700A (en) * 1996-02-20 1998-10-20 Wisconsin Alumni Research Foundation Ortho-quinone derivatives novel synthesis therefor and their use in the inhibition of neoplastic cell growth
DE60031268T2 (de) * 1999-04-14 2007-05-24 Dana-Farber Cancer Institute, Inc., Boston Verfahren und zusammansetzung zur behandlung von krebs
CA2492772A1 (en) * 2002-07-17 2004-01-22 Chiang J. Li Activated checkpoint therapy and methods of use thereof

Also Published As

Publication number Publication date
TW200510367A (en) 2005-03-16
MXPA05005314A (es) 2005-10-19
AU2003295738A1 (en) 2004-06-15
AR056613A1 (es) 2007-10-17
US20040266857A1 (en) 2004-12-30
BR0316296A (pt) 2005-12-13
WO2004045557A3 (en) 2004-08-12
CN1729183A (zh) 2006-02-01
EA200500849A1 (ru) 2006-02-24
EP1567515A2 (en) 2005-08-31
JP2006508147A (ja) 2006-03-09
WO2004045557A2 (en) 2004-06-03
EP1567515A4 (en) 2008-04-23

Similar Documents

Publication Publication Date Title
CA2506340A1 (en) Novel lapachone compounds and methods of use thereof
Al-Said et al. Anti-breast cancer activity of some novel 1, 2-dihydropyridine, thiophene and thiazole derivatives
Xia et al. Antitumor agents. Part 226: synthesis and cytotoxicity of 2-phenyl-4-quinolone acetic acids and their esters
CN101805390A (zh) 一种雷公藤红素衍生物及其用途
DE69913697T2 (de) Naphtho- und dihydrobenzothiophenderivate als cytotoxische antitumormittel
AU2005316739A1 (en) Spiro derivatives as lipoxygenase inhibitors
EP1551392A2 (en) Novel lapacho compounds and methods of use thereof
DK2152686T3 (en) HYDROXYSULFONAT OF quinone compounds AND THEIR USES
Malayeri et al. Synthesis and biological evaluation of benzo [b] furo [3, 4-e][1, 4] diazepin-1-one derivatives as anti-cancer agents
Tsang et al. The Use of Naphthoquinones and Furano-naphthoquinones as Anti-invasive Agents
US8067459B2 (en) Lapachone compounds and methods of use thereof
KR20050089007A (ko) 신규한 라파콘 화합물 및 이의 사용 방법
El-Gogary et al. Synthesis and photooxygenation of angular furocoumarins: isopsedopsoralen and allopsoralen
WO2001017988A1 (en) Novel chalcones
WO2006128120A2 (en) Novel lapachone compounds and methods of use thereof
AU2014207125B2 (en) Helquat derivatives, preparation thereof, and use thereof as medicaments
CN101115734A (zh) 作为脂氧化酶抑制剂的螺环衍生物
JP2001506624A (ja) ポリチオフェン抗腫瘍剤
HK1139411B (en) Hydroxy sulfonate of quinone compounds and their uses
FLETCHER et al. Derivatives of Fluorene. XI. New Nitrogen Mustards1
MXPA01009322A (en) Pharmaceutical composition based on polyaromatic compounds

Legal Events

Date Code Title Description
FZDE Discontinued